Biochemical Pharmacology volume 80, issue 3, P370-380 2010 DOI: 10.1016/j.bcp.2010.04.023 View full text
|
|
Share
Dario Gallotta, Patrizia Nigro, Roberta Cotugno, Patrizia Gazzerro, Maurizio Bifulco, Maria Antonietta Belisario

Abstract: AbstractRimonabant (SR141716), a cannabinoid CB1 receptor antagonist known for anti-obesity activity, has more recently been shown to inhibit tumor cell growth. Here we demonstrated the anti-tumor potential of SR141716 in leukemia-derived cell lines and its low toxicity in normal cells (PBMC). SR141716(1-20 M range of doses) reduced Jurkat and U937 cell number by activating death signals as well as affecting cell cycle progression. The most prominent response in U937 to SR141716 was a G 0 /G 1 block, while i…

expand abstract